Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease

Giuseppe Di Lorenzo, Riccardo Autorino, Michele De Laurentiis, Roberto Bianco, Rossella Lauria, Antonio Giordano, Marco De Sio, Massimino D'Armiento, Angelo Raffaele Bianco, Sabino De Placido

Research output: Contribution to journalArticle

Abstract

Prostate cancer that no longer responds to hormonal manipulation can be defined as hormone-refractory prostate cancer. Until recently, there has been no standard chemotherapeutic approach for hormone-refractory prostate cancer. The major benefits of chemotherapy in the treatment of the disease are palliative in nature, in terms of reduction of pain and use of analgesics and improvement of performance status, as followed in the most recent trials. Phase III studies are necessary to better evaluate the efficacy of the different regimens, because several old studies suffer for methodological deficits. There is a promising activity of new drug combinations, such as vinca alkaloids and taxanes. Phase I and II trial are testing combinations of classic chemotherapeutic agents and biologic drugs, and the first results appear interesting. In this article, recent advances in the treatment of hormone-refractory prostate cancer using chemotherapeutic regimens are critically reviewed.

Original languageEnglish
Pages (from-to)349-360
Number of pages12
JournalTumori
Volume89
Issue number4
Publication statusPublished - Jul 2003

Fingerprint

Disease Management
Prostatic Neoplasms
Hormones
Vinca Alkaloids
Taxoids
Biological Factors
Drug Combinations
Palliative Care
Analgesics
Drug Therapy
Pain
Pharmaceutical Preparations
Therapeutics

Keywords

  • Chemotherapy
  • Hormone-refractory prostate cancer
  • Treatment

ASJC Scopus subject areas

  • Cancer Research

Cite this

Di Lorenzo, G., Autorino, R., De Laurentiis, M., Bianco, R., Lauria, R., Giordano, A., ... De Placido, S. (2003). Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. Tumori, 89(4), 349-360.

Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. / Di Lorenzo, Giuseppe; Autorino, Riccardo; De Laurentiis, Michele; Bianco, Roberto; Lauria, Rossella; Giordano, Antonio; De Sio, Marco; D'Armiento, Massimino; Bianco, Angelo Raffaele; De Placido, Sabino.

In: Tumori, Vol. 89, No. 4, 07.2003, p. 349-360.

Research output: Contribution to journalArticle

Di Lorenzo, G, Autorino, R, De Laurentiis, M, Bianco, R, Lauria, R, Giordano, A, De Sio, M, D'Armiento, M, Bianco, AR & De Placido, S 2003, 'Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease', Tumori, vol. 89, no. 4, pp. 349-360.
Di Lorenzo, Giuseppe ; Autorino, Riccardo ; De Laurentiis, Michele ; Bianco, Roberto ; Lauria, Rossella ; Giordano, Antonio ; De Sio, Marco ; D'Armiento, Massimino ; Bianco, Angelo Raffaele ; De Placido, Sabino. / Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. In: Tumori. 2003 ; Vol. 89, No. 4. pp. 349-360.
@article{3b5212c9a6714bb187ecd540c9767333,
title = "Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease",
abstract = "Prostate cancer that no longer responds to hormonal manipulation can be defined as hormone-refractory prostate cancer. Until recently, there has been no standard chemotherapeutic approach for hormone-refractory prostate cancer. The major benefits of chemotherapy in the treatment of the disease are palliative in nature, in terms of reduction of pain and use of analgesics and improvement of performance status, as followed in the most recent trials. Phase III studies are necessary to better evaluate the efficacy of the different regimens, because several old studies suffer for methodological deficits. There is a promising activity of new drug combinations, such as vinca alkaloids and taxanes. Phase I and II trial are testing combinations of classic chemotherapeutic agents and biologic drugs, and the first results appear interesting. In this article, recent advances in the treatment of hormone-refractory prostate cancer using chemotherapeutic regimens are critically reviewed.",
keywords = "Chemotherapy, Hormone-refractory prostate cancer, Treatment",
author = "{Di Lorenzo}, Giuseppe and Riccardo Autorino and {De Laurentiis}, Michele and Roberto Bianco and Rossella Lauria and Antonio Giordano and {De Sio}, Marco and Massimino D'Armiento and Bianco, {Angelo Raffaele} and {De Placido}, Sabino",
year = "2003",
month = "7",
language = "English",
volume = "89",
pages = "349--360",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease

AU - Di Lorenzo, Giuseppe

AU - Autorino, Riccardo

AU - De Laurentiis, Michele

AU - Bianco, Roberto

AU - Lauria, Rossella

AU - Giordano, Antonio

AU - De Sio, Marco

AU - D'Armiento, Massimino

AU - Bianco, Angelo Raffaele

AU - De Placido, Sabino

PY - 2003/7

Y1 - 2003/7

N2 - Prostate cancer that no longer responds to hormonal manipulation can be defined as hormone-refractory prostate cancer. Until recently, there has been no standard chemotherapeutic approach for hormone-refractory prostate cancer. The major benefits of chemotherapy in the treatment of the disease are palliative in nature, in terms of reduction of pain and use of analgesics and improvement of performance status, as followed in the most recent trials. Phase III studies are necessary to better evaluate the efficacy of the different regimens, because several old studies suffer for methodological deficits. There is a promising activity of new drug combinations, such as vinca alkaloids and taxanes. Phase I and II trial are testing combinations of classic chemotherapeutic agents and biologic drugs, and the first results appear interesting. In this article, recent advances in the treatment of hormone-refractory prostate cancer using chemotherapeutic regimens are critically reviewed.

AB - Prostate cancer that no longer responds to hormonal manipulation can be defined as hormone-refractory prostate cancer. Until recently, there has been no standard chemotherapeutic approach for hormone-refractory prostate cancer. The major benefits of chemotherapy in the treatment of the disease are palliative in nature, in terms of reduction of pain and use of analgesics and improvement of performance status, as followed in the most recent trials. Phase III studies are necessary to better evaluate the efficacy of the different regimens, because several old studies suffer for methodological deficits. There is a promising activity of new drug combinations, such as vinca alkaloids and taxanes. Phase I and II trial are testing combinations of classic chemotherapeutic agents and biologic drugs, and the first results appear interesting. In this article, recent advances in the treatment of hormone-refractory prostate cancer using chemotherapeutic regimens are critically reviewed.

KW - Chemotherapy

KW - Hormone-refractory prostate cancer

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0142073762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142073762&partnerID=8YFLogxK

M3 - Article

C2 - 14606635

AN - SCOPUS:0142073762

VL - 89

SP - 349

EP - 360

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 4

ER -